Literature DB >> 21538511

A clinician's guide to X-linked hypophosphatemia.

Thomas O Carpenter1, Erik A Imel, Ingrid A Holm, Suzanne M Jan de Beur, Karl L Insogna.   

Abstract

X-linked hypophosphatemia (XLH) is the prototypic disorder of renal phosphate wasting, and the most common form of heritable rickets. Physicians, patients, and support groups have all expressed concerns about the dearth of information about this disease and the lack of treatment guidelines, which frequently lead to missed diagnoses or mismanagement. This perspective addresses the recommendation by conferees for the dissemination of concise and accessible treatment guidelines for clinicians arising from the Advances in Rare Bone Diseases Scientific Conference held at the NIH in October 2008. We briefly review the clinical and pathophysiologic features of the disorder and offer this guide in response to the conference recommendation, based on our collective accumulated experience in the management of this complex disorder.
Copyright © 2011 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Year:  2011        PMID: 21538511      PMCID: PMC3157040          DOI: 10.1002/jbmr.340

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  40 in total

1.  Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule.

Authors:  Ming Chang Hu; Mingjun Shi; Jianning Zhang; Johanne Pastor; Teruyo Nakatani; Beate Lanske; M Shawkat Razzaque; Kevin P Rosenblatt; Michel G Baum; Makoto Kuro-o; Orson W Moe
Journal:  FASEB J       Date:  2010-05-13       Impact factor: 5.191

Review 2.  Recent advances in renal phosphate handling.

Authors:  Emily G Farrow; Kenneth E White
Journal:  Nat Rev Nephrol       Date:  2010-02-23       Impact factor: 28.314

3.  Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets.

Authors:  Outi Mäkitie; Sang Whay Kooh; Etienne Sochett
Journal:  Clin Endocrinol (Oxf)       Date:  2003-02       Impact factor: 3.478

4.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

5.  Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene.

Authors:  Varda Levy-Litan; Eli Hershkovitz; Luba Avizov; Neta Leventhal; Dani Bercovich; Vered Chalifa-Caspi; Esther Manor; Sophia Buriakovsky; Yair Hadad; James Goding; Ruti Parvari
Journal:  Am J Hum Genet       Date:  2010-02-04       Impact factor: 11.025

6.  Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice.

Authors:  Guoying Liang; Lee D Katz; Karl L Insogna; Thomas O Carpenter; Carolyn M Macica
Journal:  Calcif Tissue Int       Date:  2009-07-17       Impact factor: 4.333

7.  Metabolic control and growth during exclusive growth hormone treatment in X-linked hypophosphatemic rickets.

Authors:  Outi Makitie; Sanna Toiviainen-Salo; Eino Marttinen; Ilkka Kaitila; Etienne Sochett; Ilkka Sipila
Journal:  Horm Res       Date:  2008-01-21

8.  Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets.

Authors:  O Mäkitie; A Doria; S W Kooh; W G Cole; A Daneman; E Sochett
Journal:  J Clin Endocrinol Metab       Date:  2003-08       Impact factor: 5.958

9.  Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia.

Authors:  Yukiko Aono; Yuji Yamazaki; Junichi Yasutake; Takehisa Kawata; Hisashi Hasegawa; Itaru Urakawa; Toshiro Fujita; Michihito Wada; Takeyoshi Yamashita; Seiji Fukumoto; Takashi Shimada
Journal:  J Bone Miner Res       Date:  2009-11       Impact factor: 6.741

10.  Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets.

Authors:  Uri S Alon; Rachel Levy-Olomucki; Wayne V Moore; Jason Stubbs; Shiguang Liu; L Darryl Quarles
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-06       Impact factor: 8.237

View more
  163 in total

Review 1.  The expanding family of hypophosphatemic syndromes.

Authors:  Thomas O Carpenter
Journal:  J Bone Miner Metab       Date:  2011-12-14       Impact factor: 2.626

2.  Evaluation of hypophosphatemia: lessons from patients with genetic disorders.

Authors:  Justine Bacchetta; Isidro B Salusky
Journal:  Am J Kidney Dis       Date:  2011-11-09       Impact factor: 8.860

3.  Novel NaPi-IIc mutations causing HHRH and idiopathic hypercalciuria in several unrelated families: long-term follow-up in one kindred.

Authors:  Y Yu; S R Sanderson; M Reyes; A Sharma; N Dunbar; T Srivastava; H Jüppner; C Bergwitz
Journal:  Bone       Date:  2012-02-24       Impact factor: 4.398

4.  X-linked hypophosphatemic rickets (PHEX mutation): A case report and literature review.

Authors:  Badi Alenazi; M A Maleque Molla; Abdullah Alshaya; Mahmoud Saleh
Journal:  Sudan J Paediatr       Date:  2017

5.  Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice.

Authors:  Andrew C Karaplis; Xiuying Bai; Jean-Pierre Falet; Carolyn M Macica
Journal:  Endocrinology       Date:  2012-10-04       Impact factor: 4.736

6.  High bone mineral apparent density in children with X-linked hypophosphatemia.

Authors:  S S Beck-Nielsen; K Brixen; J Gram; C Mølgaard
Journal:  Osteoporos Int       Date:  2013-02-07       Impact factor: 4.507

Review 7.  Use of calcimimetics in children with normal kidney function.

Authors:  Judith Sebestyen VanSickle; Tarak Srivastava; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2018-03-19       Impact factor: 3.714

8.  Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23.

Authors:  Erik A Imel; Xiaoping Zhang; Mary D Ruppe; Thomas J Weber; Mark A Klausner; Takahiro Ito; Maria Vergeire; Jeffrey S Humphrey; Francis H Glorieux; Anthony A Portale; Karl Insogna; Munro Peacock; Thomas O Carpenter
Journal:  J Clin Endocrinol Metab       Date:  2015-04-28       Impact factor: 5.958

Review 9.  DIAGNOSIS OF ENDOCRINE DISEASE: Mosaic disorders of FGF23 excess: Fibrous dysplasia/McCune-Albright syndrome and cutaneous skeletal hypophosphatemia syndrome.

Authors:  Luis F de Castro; Diana Ovejero; Alison M Boyce
Journal:  Eur J Endocrinol       Date:  2020-05       Impact factor: 6.664

10.  Inherited disorders of calcium and phosphate metabolism.

Authors:  Jyothsna Gattineni
Journal:  Curr Opin Pediatr       Date:  2014-04       Impact factor: 2.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.